Etoposide plus benmelstobart for elderly extensive small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two medicines (etoposide and benmelstobart) followed by a maintenance treatment with benmelstobart and anlotinib for older adults with extensive-stage small cell lung cancer. The goal is to see if this treatment helps control the cancer and is safe for patients who may not tolerate standard platinum-based chemo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 70 and 85 years old.
- You have been diagnosed with extensive-stage small cell lung cancer (cancer that has spread beyond the lung).
- You have not had any prior chemo, immunotherapy, or targeted treatment for this cancer.
- You are in fairly good daily health (able to care for yourself, though you may need some help).
- You have at least one tumor that can be seen on a CT scan, and your life expectancy is at least 3 months.
- Your blood counts, liver, kidney, and heart tests must be within acceptable limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of benmelstobart (an immunotherapy drug), anlotinib (a targeted therapy that blocks blood vessel growth), chemotherapy, and chest radiation for people with extensive-stage small cell lung cancer (cancer that has spread beyond one lung). The goal is to see if this combination helps shrink tumors and control the disease better than standard care.
This study tests a combination of three drugs (bevacizumab, anlotinib, and etoposide) as the first treatment for small-cell lung cancer that has spread. It is designed for older patients or those who cannot tolerate standard intensive chemotherapy, with the goal of controlling the cancer while being gentler on the body.
This trial tests a combination of two drugs—adebrelimab (an immunotherapy) and etoposide (a chemotherapy pill)—for people with advanced small cell lung cancer who are older (65+) or not in good physical shape. The goal is to see if this treatment works well and is safe for patients who might not tolerate more intense therapy.
This trial tests a new combination of an immunotherapy drug, a targeted therapy, and standard chemotherapy plus radiation for people with limited-stage small cell lung cancer. It aims to see if this combination improves outcomes compared to standard treatment alone.
This trial tests a new combination of two drugs (bempemab and anlotinib) as a first treatment for older adults with advanced lung cancer. The goal is to see if this drug pair can shrink tumors and slow the cancer, possibly without the need for chemo or radiation.
Hear when a new ELDERLY PEOPLE trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.